OGA and Alzheimer disease: Therefore, the elevation of O-GlcNAcylation with O-GlcNAcase inhibitors are proposed as a novel therapy for (Alzheimer’s disease) AD (Arnold et al., 1996; Liu et al., 2004; Morris et al., 2015; Bartolome-Nebreda et al., 2021).